BOOK
Molecular Pathology: Predictive, Prognostic, and Diagnostic Markers in Tumors, An Issue of Surgical Pathology Clinics, E-Book
(2016)
Additional Information
Book Details
Abstract
This issue of the Surgical Pathology Clinics entitled “Molecular Pathology: Predictive, Prognostic, and Diagnostic Markers in Tumors is being edited by Dr. Lynette Sholl and will cover molecular pathology in a wide array of anatomic locations including, salivary gland, lung, bladder, glioma, endometrium, colon, pancreaticobiliary tract, sarcoma, myeloid neoplasams, and lymphomas.
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| Molecular Pathology:Predictive, Prognostic,and Diagnostic Markersin Tumors\r | i | ||
| Copyright\r | ii | ||
| Contributors | iii | ||
| CONSULTING EDITOR | iii | ||
| EDITOR | iii | ||
| AUTHORS | iii | ||
| Contents | v | ||
| Preface\r | v | ||
| Molecular Pathology: Predictive, Prognostic, and Diagnostic Markers in Salivary Gland Tumors\r | v | ||
| The Molecular Pathology of Lung Cancer\r | v | ||
| Establishing a Robust Molecular Taxonomy for Diffuse Gliomas of Adulthood\r | v | ||
| The Emerging Molecular Landscape of Urothelial Carcinoma\r | v | ||
| Molecular Pathology: Predictive, Prognostic, and Diagnostic Markers in Uterine Tumors\r | vi | ||
| Molecular Evaluation of Colorectal Adenocarcinoma: Current Practice and Emerging Concepts\r | vi | ||
| Molecular Diagnostics in the Evaluation of Pancreatic Cysts\r | vi | ||
| Molecular Pathogenesis and Diagnostic, Prognostic and Predictive Molecular Markers in Sarcoma\r | vii | ||
| Molecular Pathology: Prognostic and Diagnostic Genomic Markers for Myeloid Neoplasms\r | vii | ||
| Molecular Pathology: Predictive, Prognostic, and Diagnostic Markers in Lymphoid Neoplasms\r | vii | ||
| SURGICAL PATHOLOGY CLINICS\r | viii | ||
| FORTHCOMING ISSUES | viii | ||
| December 2016 | viii | ||
| March 2017 | viii | ||
| June 2017 | viii | ||
| RECENT ISSUES | viii | ||
| June 2016 | viii | ||
| March 2016 | viii | ||
| December 2015 | viii | ||
| Preface | ix | ||
| Molecular Pathology | 339 | ||
| ABSTRACT | 339 | ||
| OVERVIEW | 339 | ||
| ASSOCIATED GENETIC CHANGES/ALTERATIONS | 340 | ||
| DIAGNOSIS-DEFINING MOLECULAR ALTERATIONS: A NEW PARADIGM IN MONOMORPHIC SALIVARY GLAND TUMORS | 340 | ||
| HIGH-GRADE PLEOMORPHIC SALIVARY GLAND MALIGNANCIES: THE IMPORTANCE OF WALKING BEFORE RUNNING IN APPLYING ANCILLARY STUDIES | 341 | ||
| MOLECULAR PATHOLOGY OF CLASSIC/COMMON TUMORS | 341 | ||
| MUCOEPIDERMOID CARCINOMA | 341 | ||
| ADENOID CYSTIC CARCINOMA | 342 | ||
| SALIVARY DUCT CARCINOMA | 343 | ||
| MAMMARY ANALOG SECRETORY CARCINOMA | 344 | ||
| POLYMORPHOUS LOW-GRADE ADENOCARCINOMA/CRIBRIFORM ADENOCARCINOMA OF SALIVARY GLAND | 344 | ||
| PLEOMORPHIC ADENOMA AND CARCINOMA EX PLEOMORPHIC ADENOMA | 346 | ||
| MOLECULAR PATHOLOGY OF RARE TUMORS | 346 | ||
| HYALINIZING CLEAR CELL CARCINOMA | 346 | ||
| BASAL CELL ADENOMA AND ADENOCARCINOMA | 347 | ||
| EPITHELIAL-MYOEPITHELIAL CARCINOMA | 348 | ||
| MYOEPITHELIAL CARCINOMA | 348 | ||
| TECHNIQUES | 348 | ||
| REFERENCES | 349 | ||
| The Molecular Pathology of Lung Cancer | 353 | ||
| ABSTRACT | 353 | ||
| OVERVIEW | 353 | ||
| ASSOCIATED GENETIC ALTERATIONS | 354 | ||
| ADENOCARCINOMA | 354 | ||
| SQUAMOUS CELL CARCINOMA | 354 | ||
| SMALL CELL LUNG CARCINOMA/LARGE CELL NEUROENDOCRINE CARCINOMA | 354 | ||
| MOLECULAR PATHOLOGY OF CLASSIC TUMORS | 356 | ||
| INVASIVE LUNG ADENOCARCINOMA | 356 | ||
| ADENOCARCINOMA IN SITU/MINIMALLY INVASIVE ADENOCARCINOMA | 357 | ||
| INVASIVE MUCINOUS ADENOCARCINOMAS | 359 | ||
| THE GENOMIC BASIS OF MORPHOLOGIC HETEROGENEITY | 359 | ||
| MOLECULAR PATHOLOGY OF RARE TUMORS | 361 | ||
| LARGE CELL CARCINOMA | 361 | ||
| ADENOSQUAMOUS CARCINOMA | 363 | ||
| PLEOMORPHIC CARCINOMA | 363 | ||
| LYMPHOEPITHELIAL-LIKE CARCINOMA | 363 | ||
| NUT CARCINOMA | 363 | ||
| PRIMARY SALIVARY GLAND TUMORS OF THE LUNG | 365 | ||
| PAPILLARY TUMORS OF THE LUNG/CILIATED MICRONODULAR PAPILLARY TUMOR | 367 | ||
| TECHNIQUES | 369 | ||
| MOLECULAR METHODS | 369 | ||
| FLUORESCENCE IN SITU HYBRIDIZATION | 373 | ||
| IMMUNOHISTOCHEMISTRY | 373 | ||
| REFERENCES | 373 | ||
| Establishing a Robust Molecular Taxonomy for Diffuse Gliomas of Adulthood | 379 | ||
| ABSTRACT | 379 | ||
| OVERVIEW | 379 | ||
| MUTATIONS IN ISOCITRATE DEHYDROGENASE GENES DISTINGUISH LOWER-GRADE GLIOMAS FROM GLIOBLASTOMA | 380 | ||
| A DEFINED SET OF GENOMIC ABNORMALITIES ROBUSTLY DESIGNATES LOWER-GRADE GLIOMA SUBTYPE | 382 | ||
| ISOCITRATE DEHYDROGENASE–WILD-TYPE GLIOMAS: GLIOBLASTOMA AND BEYOND | 383 | ||
| MOVING TOWARD MORE BIOLOGICALLY RELEVANT GLIOMA SUBCLASSIFICATION | 385 | ||
| MOLECULAR EVOLUTION OF GLIOMA IN THE CONTEXT OF THERAPY | 387 | ||
| SUMMARY AND IMPLICATIONS/IMPACT | 388 | ||
| REFERENCES | 388 | ||
| The Emerging Molecular Landscape of Urothelial Carcinoma | 391 | ||
| ABSTRACT | 391 | ||
| OVERVIEW | 391 | ||
| MOLECULAR PATHOLOGY FEATURES OF UROTHELIAL CARCINOMA | 395 | ||
| TWO-PATHWAY MODEL | 395 | ||
| NONINVASIVE LOW-GRADE PAPILLARY CARCINOMA | 395 | ||
| HIGH-GRADE IN SITU AND INVASIVE DISEASE | 396 | ||
| EARLY SHARED ALTERATIONS | 398 | ||
| FURTHER SUBDIVIDING INVASIVE DISEASE BASED ON MOLECULAR PATHWAYS | 398 | ||
| THERAPEUTIC AND PROGNOSTIC TARGETS | 399 | ||
| SUMMARY | 401 | ||
| REFERENCES | 402 | ||
| Molecular Pathology | 405 | ||
| ABSTRACT | 405 | ||
| OVERVIEW | 405 | ||
| HISTOLOGIC SUBTYPES OF ENDOMETRIAL CARCINOMA (WORLD HEALTH ORGANIZATION CLASSIFICATION) | 405 | ||
| ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | 405 | ||
| SEROUS CARCINOMA OF THE ENDOMETRIUM | 406 | ||
| CLEAR CELL CARCINOMA OF THE ENDOMETRIUM | 406 | ||
| MUCINOUS ADENOCARCINOMA | 406 | ||
| UNDIFFERENTIATED/DEDIFFERENTIATED CARCINOMA | 406 | ||
| NEUROENDOCRINE CARCINOMA | 407 | ||
| MIXED-TYPE ENDOMETRIAL CARCINOMA | 407 | ||
| CARCINOSARCOMA | 408 | ||
| MORPHOLOGICALLY AMBIGUOUS HIGH-GRADE ENDOMETRIAL ADENOCARCINOMA | 408 | ||
| MOLECULAR SUBTYPES OF ENDOMETRIAL CARCINOMA AND THEIR MORPHOLOGIC CORRELATES | 408 | ||
| ULTRAMUTATED (POLE-MUTATED) ENDOMETRIAL CARCINOMAS | 409 | ||
| MICROSATELLITE INSTABILITY ENDOMETRIAL CANCERS (HYPERMUTATED) | 409 | ||
| LOW-COPY-NUMBER ENDOMETRIAL CARCINOMAS | 410 | ||
| HIGH-COPY-NUMBER ENDOMETRIAL CARCINOMA (SEROUS-LIKE) | 410 | ||
| Molecular Features of Clear Cell Carcinomas | 411 | ||
| Molecular Features of Undifferentiated/Dedifferentiated Carcinomas | 411 | ||
| Molecular Features of Neuroendocrine Carcinomas | 411 | ||
| Molecular Features of Mucinous Endometrial Carcinoma | 411 | ||
| Molecular Features of Carcinosarcomas | 411 | ||
| PROBLEMATIC AREAS IN THE CLASSIFICATION OF ENDOMETRIAL CARCINOMAS AND THE USE OF MOLECULAR ALTERATIONS AS DIAGNOSTIC TOOLS | 412 | ||
| PROGNOSTIC BIOMARKERS IN UTERINE CARCINOMAS | 413 | ||
| PREDICTIVE BIOMARKERS IN UTERINE CANCER | 414 | ||
| HEREDITARY ENDOMETRIAL CARCINOMA | 414 | ||
| MOLECULAR FEATURES OF MALIGNANT UTERINE MESENCHYMAL NEOPLASMS | 417 | ||
| UTERINE LEIOMYOSARCOMA | 417 | ||
| ENDOMETRIAL STROMAL SARCOMA | 417 | ||
| REFERENCES | 418 | ||
| Molecular Evaluation of Colorectal Adenocarcinoma | 427 | ||
| ABSTRACT | 427 | ||
| OVERVIEW | 427 | ||
| MISMATCH REPAIR–DEFICIENT TUMORS AND LYNCH SYNDROME | 428 | ||
| MISMATCH REPAIR PROTEIN EXPRESSION | 429 | ||
| MICROSATELLITE INSTABILITY TESTING | 431 | ||
| MLH1 PROMOTER METHYLATION AND BRAF MUTATION STATUS IN MISMATCH REPAIR–DEFICIENT COLORECTAL CARCINOMA | 433 | ||
| TEST INTEGRATION FOR ASSESSING MISMATCH REPAIR PATHWAY STATUS | 433 | ||
| PROGNOSTIC AND THERAPEUTIC SIGNIFICANCE OF MISMATCH REPAIR DEFICIENCY | 434 | ||
| MISMATCH REPAIR DEFICIENCY AND PROGRAMMED DEATH-1 INHIBITOR THERAPY | 435 | ||
| THE EPIDERMAL GROWTH FACTOR RECEPTOR PATHWAY AND INHIBITORS | 435 | ||
| EPIDERMAL GROWTH FACTOR RECEPTOR AND THE RAS/RAF/MEK/ERK PATHWAY | 435 | ||
| EPIDERMAL GROWTH FACTOR RECEPTOR AND THE PHOSPHATIDYLINOSITOL-3-KINASE/AKT/MAMMALIAN TARGET OF RAPAMYCIN PATHWAY | 437 | ||
| SUMMARY AND FUTURE DIRECTIONS | 437 | ||
| REFERENCES | 438 | ||
| Molecular Diagnostics in the Evaluation of Pancreatic Cysts | 441 | ||
| ABSTRACT | 441 | ||
| OVERVIEW | 441 | ||
| PANCREATIC CANCER AND PANCREATIC CYSTS | 442 | ||
| SENDAI AND FUKUOKA GUIDELINES | 442 | ||
| AMERICAN GASTROENTEROLOGICAL ASSOCIATION GUIDELINES | 444 | ||
| PANCREATIC CYSTS AND THEIR GENETICS | 446 | ||
| INTRADUCTAL PAPILLARY MUCINOUS NEOPLASM | 446 | ||
| MUCINOUS CYSTIC NEOPLASM | 448 | ||
| SEROUS CYSTADENOMA | 449 | ||
| SOLID-PSEUDOPAPILLARY NEOPLASM | 450 | ||
| NON-NEOPLASTIC CYSTS | 450 | ||
| DIAGNOSTIC DNA TESTING OF PANCREATIC CYST FLUID | 450 | ||
| INTEGRATION OF DIAGNOSTIC DNA TESTING IN THE MANAGEMENT OF PANCREATIC CYSTS | 452 | ||
| FUTURE TRENDS | 452 | ||
| REFERENCES | 454 | ||
| Molecular Pathogenesis and Diagnostic, Prognostic and Predictive Molecular Markers in Sarcoma | 457 | ||
| ABSTRACT | 457 | ||
| OVERVIEW | 457 | ||
| SARCOMAS WITH SIMPLE GENOME | 458 | ||
| TUMORS WITH CHIMERIC TRANSCRIPTION FACTORS: VASCULAR TUMORS | 458 | ||
| TUMORS WITH DEREGULATED KINASE SIGNALING: GASTROINTESTINAL STROMAL TUMOR | 460 | ||
| TUMORS DRIVEN BY ONCOMETABOLITES (VIA EPIGENETIC DEREGULATION): CHONDROSARCOMA | 464 | ||
| TUMORS DRIVEN BY PRIMARY EPIGENETIC DEREGULATION: CHONDROBLASTOMA | 466 | ||
| SARCOMAS WITH COMPLEX GENOME | 466 | ||
| TUMORS WITH CHARACTERISTIC COPY NUMBER ALTERATIONS: DEDIFFERENTIATED LIPOSARCOMA | 467 | ||
| TUMORS WITH HIGHLY COMPLEX KARYOTYPES: OSTEOSARCOMA | 468 | ||
| REFERENCES | 468 | ||
| Molecular Pathology | 475 | ||
| ABSTRACT | 475 | ||
| OVERVIEW | 475 | ||
| KNOWLEDGE DERIVED FROM NEXT-GENERATION SEQUENCING TESTING OF MYELOID NEOPLASMS | 475 | ||
| THE SAME GENETIC ALTERATIONS ARE SHARED AMONG DIVERSE TYPES OF MYELOID NEOPLASMS | 476 | ||
| COMPLEX COMBINATION OF GENETIC ALTERATIONS IS THE RULE, NOT THE EXCEPTION | 476 | ||
| GENETIC ALTERATIONS IN THE SAME PATHWAY TEND TO BE MUTUALLY EXCLUSIVE | 476 | ||
| CLONAL HETEROGENEITY IS A WAY OF LIFE FOR MYELOID NEOPLASMS | 477 | ||
| WHEN MULTIPLE ALTERATIONS ARE PRESENT, TEMPORAL SEQUENCE OF ACQUISITION OF GENETIC ALTERATIONS VARIES AMONG DIFFERENT INDIV ... | 477 | ||
| FOCAL COPY NUMBER ALTERATIONS AND LOSS OF HETEROZYGOSITY (UNIPARENTAL DISOMY) INVISIBLE TO CONVENTIONAL CYTOGENETICS ARE CO ... | 479 | ||
| DIAGNOSTIC UTILITY OF NEXT-GENERATION SEQUENCING–BASED MOLECULAR TESTING IN MYELOID NEOPLASM | 479 | ||
| PATIENTS HAVE CYTOPENIA AND CLINICAL SUSPICION OF MYELODYSPLASIA BUT NO OVERT MORPHOLOGIC ABNORMALITY/DYSPLASIA IS SEEN IN ... | 480 | ||
| UNLIKE CYTOPENIA, MUTATIONS CAN BE DETECTED IN MOST PATIENTS WITH CYTOSIS BY NEXT-GENERATION SEQUENCING–BASED PANEL TESTING | 481 | ||
| PROGNOSTICATION IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA | 481 | ||
| MONITORING DISEASE PROGRESSION FOR PATIENTS WITH EXISTING DIAGNOSIS OF MYELOID NEOPLASM | 481 | ||
| MONITORING BEFORE AND AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION | 482 | ||
| PROGNOSTIC UTILITY OF NEXT-GENERATION SEQUENCING–BASED MOLECULAR TESTING IN MYELOID NEOPLASM | 482 | ||
| RECENT DEVELOPMENT IN PROGNOSTIC IMPACT OF GENE MUTATIONS | 483 | ||
| CEBPA GENE | 483 | ||
| ISOCITRATE DEHYDROGENASE GENES | 483 | ||
| KIT GENE | 483 | ||
| WILMS TUMOR 1 GENE | 483 | ||
| ADDITIONAL SEX COMBS GENE | 483 | ||
| DNA (CYTOSINE-5)-METHYLTRANSFERASE 3A GENE | 484 | ||
| SPLICING FACTOR 3B SUBUNIT 1 GENE | 484 | ||
| SPLICING FACTORS OTHER THAN SF3B1 (SRSF2, U2AF1, AND ZRSR2) | 484 | ||
| RUNT-RELATED TRANSCRIPTION FACTOR 1 GENE | 484 | ||
| TUMOR PROTEIN P53 GENE | 484 | ||
| SUMMARY | 484 | ||
| REFERENCES | 485 | ||
| Molecular Pathology | 489 | ||
| ABSTRACT | 489 | ||
| OVERVIEW | 489 | ||
| MATURE B-CELL LYMPHOID NEOPLASMS | 489 | ||
| CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA | 489 | ||
| Clinical Features | 489 | ||
| Histologic Features and Immunophenotypic Profile | 489 | ||
| Molecular Diagnostic and Prognostic Markers | 490 | ||
| Targeted Therapies | 493 | ||
| BURKITT LYMPHOMA | 493 | ||
| Clinical Features | 493 | ||
| Histologic Features and Immunophenotypic Profile | 493 | ||
| Molecular Diagnostic and Prognostic Markers | 493 | ||
| FOLLICULAR LYMPHOMA | 495 | ||
| Clinical Features | 495 | ||
| Histologic Features and Immunophenotypic Profile | 495 | ||
| Molecular Diagnostic and Prognostic Markers | 496 | ||
| Targeted Therapies | 496 | ||
| DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED | 496 | ||
| Clinical and Histologic Features | 496 | ||
| Molecular Diagnostic and Prognostic Markers | 498 | ||
| Targeted Therapies | 501 | ||
| HAIRY CELL LEUKEMIA | 501 | ||
| Clinical Features | 501 | ||
| Histologic Features and Immunophenotypic Profile | 501 | ||
| Molecular Diagnostic and Prognostic Markers | 501 | ||
| Targeted Therapies | 503 | ||
| LYMPHOPLASMACYTIC LYMPHOMA | 503 | ||
| Clinical, Histologic Features, and Immunophenotypic Profile | 503 | ||
| Molecular Diagnostic and Prognostic Markers | 503 | ||
| Targeted Therapies | 506 | ||
| MATURE T-CELL LYMPHOID NEOPLASMS | 506 | ||
| ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA | 506 | ||
| Clinical and Histologic Features | 506 | ||
| Histologic Features and Immunophenotypic Profile | 506 | ||
| Molecular Diagnostic and Prognostic Markers | 506 | ||
| Targeted Therapies | 510 | ||
| T-CELL LARGE GRANULAR LYMPHOCYTIC LEUKEMIA | 511 | ||
| Clinical Features | 511 | ||
| Histologic Features and Immunophenotypic Profile | 511 | ||
| Molecular Diagnostic and Prognostic Markers | 511 | ||
| Targeted Therapies | 512 | ||
| SUMMARY | 514 | ||
| REFERENCES | 514 |